L. V. Prasad Eye Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hyderabad India (1987)

Organization Overview

First Clinical Trial
2002
NCT00386958
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

LVPEI | LV Prasad Eye Institiute | L.V. Prasad Eye Institute | LV Prasad Eye Institute | LV Prasad Eye Institute (Hyderabad Eye Research Foundation) | V. S. T. Glaucoma Services, L. V. Prasad Eye Institute,

Active Ingredients

Drugs in Phase 4 Trials (1)

collagen (1 trial)

Drugs in Phase 3 Trials (2)

natamycin (natacyn) (1 trial)

voriconazole (vfend) (1 trial)

Drugs in Phase 2 Trials (3)

fluocinolone acetonide (synalar) (1 trial)

nepafenac (nevanac) (1 trial)

povidone-iodine (betadine) (1 trial)

Drugs in Phase 1 Trials (2)

ex-vivo cultivated limbal stem cell (2 trials)

stem cells (1 trial)

Drugs in Other Trials (1)

pegaptanib (macugen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blindness (Phase 2)

Corneal Injuries (Phase 1)

Corneal Ulcer (Phase 2)

Edema (Phase 2)

Glaucoma (Phase 4)

Keratitis (Phase 3)

Macular Edema (Phase 2)

Mycoses (Phase 3)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9